Rheumatologie und Hepatologie: Diagnostik und Therapie von autoimmunen Lebererkrankungen

Zusammenfassung

Unter autoimmunen Lebererkrankungen werden im klassischen Sinne 3 verschiedene Entitäten, die Autoimmune Hepatitis (AIH), die Primär biliäre Cholangitis (PBC) und die Primär sklerosierende Cholangitis (PSC) verstanden. Der nachfolgende Übersichtartikel fokusiert auf die Diagnostik und die Therapie dieser 3 autoimmunen Lebererkrankungen und gibt eine Übersicht zu möglichen zusätzlich assoziierten Autoimmunerkrankungen.

Abstract

Autoimmune liver diseases include 3 different entities, i. e. autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. This review focuses on the diagnostic and therapeutic options of autoimmune liver diseases and provides an overview of related autoimmune disorders.

Schlüsselwörter

Autoimmune Hepatitis - Primär biliäre Cholangitis - Primär sklerosierende Cholangitis

Key words

primary sclerosing cholangitis - primary biliary cholangitis - autoimmune hepatitis

Publication History

Article published online:
15 May 2019

• Literatur

• 1 Boberg KM, Aadland E, Jahnsen J. et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33: 99-103
• 2 Ngu JH, Bechly K, Chapman BA. et al. Population-based epidemiology study of autoimmune hepatitis: A disease of older women?. Journal of Gastroenterology and Hepatology 2010; 25: 1681-1686
• 3 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. Journal of Hepatology 2015; 63: 971-1004
• 4 Abe M, Mashiba T, Zeniya M. et al. Present status of autoimmune hepatitis in Japan: A nationwide survey. J Gastroenterol 2011; 46: 1136-1141
• 5 Takahashi H, Zeniya M. Acute presentation of autoimmune hepatitis: Does it exist? A published work review. Hepatol Res 2011; 41: 498-504
• 6 Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis – Update 2015. Journal of Hepatology 2015; 62: S100-S111
• 7 Hennes EM, Zeniya M, Czaja AJ. et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-176
• 8 Muratori P, Granito A, Quarneti C. et al. Autoimmune hepatitis in Italy: the Bologna experience. Journal of Hepatology 2009; 50: 1210-1218
• 9 Alvarez F, Berg PA, Bianchi FB. et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. Journal of Hepatology 1999; 31: 929-938
• 10 Czaja A. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002; 36: 479-497
• 11 Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. YGAST 1993; 105: 1824-1832
• 12 Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (federführend), Deutsche Gesellschaft für Innere Medizin (DGIM), Deutsche M. Crohn/Colitis ulcerosa Vereinigung (DCCV), Deutsche Leberhilfe e.V., Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM), Deutsche Gesellschaft für Endoskopie und Bildgebende Verfahren (DGE-BV), et al. Practice guideline autoimmune liver diseases – AWMF-Reg.No. 021-27 Z Gastroenterol 2017; 55: 1135–1226
• 13 Czaja AJ, Morshed SA, Parveen S. et al. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 1997; 26: 567-572
• 14 European Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of Hepatology 2017; 67: 145-172
• 15 Watt FE, James OFW, Jones DEJ. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: A population-based cohort study. QJM. 2004; 97: 397-406
• 16 Mang FW, Michieletti P, O'Rourke K. et al. Primary biliary cirrhosis, sicca complex, and dysphagia. Dysphagia 1997; 12: 167-170
• 17 Vergani D, Alvarez F, Bianchi FB. et al. Liver autoimmune serology: A consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. Journal of Hepatology 2004; 41: 677-683
• 18 Liu H, Norman GL, Shums Z. et al. PBC screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun 2010; 35: 436-442
• 19 Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379: 103-112
• 20 Scheuer PJ. Ludwig Symposium on biliary disorders – part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin Proc 1998; 73: 179-183
• 21 Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967; 60: 1257-1260
• 22 Corpechot C, Carrat F, Poujol-Robert A. et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012; 56: 198-208
• 23 Floreani A, Cazzagon N, Martines D. et al. Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. Dig Liver Dis 2011; 43: 887-892
• 24 Gómez-Dominguez E, Mendoza J, García-Buey L. et al. Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Alimentary Pharmacology & Therapeutics 2008; 27: 441-447
• 25 Dave M, Elmunzer BJ, Dwamena BA. et al. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. RY 2010; 256: 387-396
• 26 European Society of Gastrointestinal Endoscopy, European Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Journal of Hepatology 2017; 66: 1265-1281
• 27 Broomé U, Olsson R, Lööf L. et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-615
• 28 Lindkvist B, Benito de Valle M, Gullberg B. et al. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 2010; 52: 571-577
• 29 Tischendorf JJW, Hecker H, Krüger M. et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. The American Journal of Gastroenterology 2007; 102: 107-114
• 30 European Association for the Stud. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. Journal of Hepatology 2009; 51: 237-267
• 31 Hov J-R, Boberg KM, Karlsen TH. Autoantibodies in primary sclerosing cholangitis. WJG 2008; 14: 3781-3791
• 32 Chapman RW, Arborgh BA, Rhodes JM. et al. Primary sclerosing cholangitis: A review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-877
• 33 Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 31-39
• 34 Wiesner RH, Grambsch PM, Dickson ER. et al. Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis. Hepatology 1989; 10: 430-436
• 35 Loftus EV. PSC-IBD: A unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-96
• 36 Boonstra K, Weersma RK, van Erpecum KJ. et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58: 2045-2055
• 37 Claessen MMH, Vleggaar FP, Tytgat KMAJ. et al. High lifetime risk of cancer in primary sclerosing cholangitis. Journal of Hepatology 2009; 50: 158-164
• 38 Soetikno RM, Lin OS, Heidenreich PA. et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointestinal Endoscopy 2002; 56: 48-54
• 39 Weismüller TJ, Wedemeyer J, Kubicka S. et al. The challenges in primary sclerosing cholangitis – aetiopathogenesis, autoimmunity, management and malignancy. Journal of Hepatology 2008; 48 (Suppl. 01) S38-S57
• 40 Schramm C, Weiler-Normann C, Wiegard C. et al. Treatment response in patients with autoimmune hepatitis. Hepatology 2010; 52: 2247-2248
• 41 Manns MP, Woynarowski M, Kreisel W. et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-1206
• 42 Lüth S, Herkel J, Kanzler S. et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 2008; 42: 926-930
• 43 Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: Correlation of serum transaminase and gamma globulin levels with histologic features. YGAST 1981; 80: 687-692
• 44 Hennes EM, Oo YH, Schramm C. et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?. The American Journal of Gastroenterology 2008; 103: 3063-3070
• 45 Hlivko JT, Shiffman ML, Stravitz RT. et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin. Gastroenterol. Hepatol 2008; 6: 1036-1040
• 46 Zachou K, Gatselis N, Papadamou G. et al. Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. Journal of Hepatology 2011; 55: 636-646
• 47 Poupon RE, Lindor KD, Parés A. et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. Journal of Hepatology 2003; 39: 12-16
• 48 Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. YGAST 2006; 130: 715-720
• 49 Rudic JS, Poropat G, Krstic MN. et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012; 12: CD000551
• 50 Corpechot C, Abenavoli L, Rabahi N. et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48: 871-877
• 51 Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. Journal of Hepatology 2011; 55: 1361-1367
• 52 Schaap FG, Trauner M, Jansen PLM. Bile acid receptors as targets for drug development. Nature Reviews Gastroenterology &. Hepatology 2014; 11: 55-67
• 53 Gomez-Ospina N, Potter CJ, Xiao R. et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Comms 2016; 7: 10713
• 54 Nevens F, Andreone P, Mazzella G. et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med 2016; 375: 631-643
• 55 Corpechot C, Chazouillères O, Rousseau A. et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med 2018; 378: 2171-2181